UAE Cancer Immunotherapy Market Size & Outlook, 2023-2030
UAE cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
UAE cancer immunotherapy market highlights
- The UAE cancer immunotherapy market generated a revenue of USD 298.7 million in 2023 and is expected to reach USD 503.9 million by 2030.
- The UAE market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 298.7 million |
| Market revenue in 2030 | USD 503.9 million |
| Growth rate | 7.8% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, UAE accounted for 0.2% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Kuwait is the fastest growing regional market in Middle East & Africa and is projected to reach USD 103.7 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 66.32% in 2023. Horizon Databook has segmented the UAE cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
The cancer immunotherapy market in UAE is expected to witness steady growth due to economic developments in the region, increase in the prevalence of cancer, high healthcare expenditure, and rise in consumer awareness about the disease. Favorable initiatives in the public and private sectors to curb financial constraints are also contributing to market growth.
For instance, Cleveland Clinic Abu Dhabi became the first cancer center in UAE in April 2018. The ground-breaking cancer center will cover the treatment cost of all patients with a life-threatening condition who are unable to afford the treatment.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UAE cancer immunotherapy market size, by product, 2018-2030 (US$M)
UAE Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
